<DOC>
	<DOCNO>NCT02269228</DOCNO>
	<brief_summary>To investigate occurrence dipyridamole associate headache healthy subject use titration scheme</brief_summary>
	<brief_title>Tolerability Asasantin Healthy Female Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Aspirin , Dipyridamole Drug Combination</mesh_term>
	<criteria>All participant study healthy females/males , range 18 55 year age within Broca Index ≥ 20 % ≤ + 20 % Prior admission study subject give , accordance good clinical practice ( GCP ) local legislation , write informed consent . Subjects exclude study result medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Subjects know gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Subjects diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Subjects know history orthostatic hypotension , faint spell blackouts Subjects chronic relevant acute infection Subjects history allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Subjects take drug long halflife ( &gt; 24 hour ) ( ≤ 1 month prior administration trial ) Subjects receive drug might influence result trial ( ≤ 10 day prior administration trial ) Subjects participate another study investigational drug ( ≤ 1 month prior administration trial ) Subjects smoke 15 cigarette 4 cigar 4 pipes/day Subjects able refrain excessive consumption methylxanthine contain drink food Subjects drink 60 g alcohol per day Subjects dependent drug Subjects donate blood ( &gt; 400 ml ) ( ≤ 4 week prior administration trial ) Subjects participated excessive physical activity ( ≤ 5 day prior administration trial ) For female subject : Pregnancy Positive pregnancy test No adequate contraception ( acceptable : e.g . sterilisation , intrauterine device ( IUD ) , oral contraceptive , condom ) Inability maintain adequate contraception whole study period Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>